Showing results (11-20 of 652) with videos related to
Sort By:
Pageof 66
Statistics in Medicine|September 21, 2022
BOB: Bayesian optimal design for biosimilar trials with co-primary endpointsXiaohan Chi, Zhangsheng Yu, Ruitao LinPharmaceutical Statistics|February 9, 2023
Bayesian single-to-double arm transition design using both short-term and long-term endpointsTianlin Xu, Haolun Shi, Ruitao LinBiostatistics (Oxford, England)|July 23, 2021
Bayesian adaptive model selection design for optimal biological dose finding in phase I/II clinical trialsRuitao Lin, Guosheng Yin, Haolun ShiTherapeutic Innovation & Regulatory Science|August 20, 2025
BOP2-Comb: Bayesian Optimal Phase II Design for Optimizing Doses and Assessing Contribution of Components in Drug CombinationsXiaohan Chi, Ying Yuan, Ruitao LinBiometrics|June 24, 2025
COCA: a randomized Bayesian design integrating dose optimization and component contribution assessment for combination therapiesXiaohan Chi, Ruitao Lin, Ying YuanBiometrics|September 9, 2024
High-dimensional multivariate analysis of variance via geometric median and bootstrappingGuanghui Cheng, Ruitao Lin, Liuhua PengBiometrical Journal. Biometrische Zeitschrift|May 13, 2024
Comparative review of novel model-assisted designs for phase I/II clinical trialsHaolun Shi, Ruitao Lin, Xiaolei LinPharmaceutical Statistics|May 19, 2021
The use of local and nonlocal priors in Bayesian test-based monitoring for single-arm phase II clinical trialsYanhong Zhou, Ruitao Lin, J Jack LeeJournal of the American Statistical Association|May 18, 2022
BAGS: A Bayesian Adaptive Group Sequential Trial Design With Subgroup-Specific Survival ComparisonsRuitao Lin, Peter F Thall, Ying YuanBayesian Analysis|July 16, 2021
A Phase I-II Basket Trial Design to Optimize Dose-Schedule Regimes Based on Delayed OutcomesRuitao Lin, Peter F Thall, Ying YuanPageof 66